Cleveland Diagnostics is expanding access to IsoPSA, its novel test for prostate cancer, by entering into an agreement with Quest Diagnostics
The blood-based, non-invasive IsoPSA test is used prior to an initial biopsy to assess the likelihood that a patient has high-grade prostate cancer. By the middle of this year, patients nationwide will be able to access IsoPSA. Specifically, once the test is ordered by their doctor, patients will be able to “provide a blood specimen […]